2017-11-20 16:50:23 UTC

IBD Drug Monitoring: Where Do You Stand?

Nov. 27, 2017

When it comes to being proactive or reactive, which method makes the most sense?

Therapeutic drug monitoring (TDM) is used when treating inflammatory bowel disease (IBD) patients to determine the amount of IBD drugs in the blood to make sure that patients are getting optimal levels of their drug. The goal of TDM is to help guide treatment changes. But does it make sense to proactively monitor patients or should a reactive approach be taken?

Su Bin Kim, MD, and Maria T. Abreu, MD, AGAF, make the case, in AGA Perspectives, for a proactive approach to TDM, as that will maximize efficacy and minimize toxicity in IBD patients.

Maisa Abdalla, MD, MPH, and Hans Herfarth, MD, PhD, hold that while being proactive is attractive, trough and anti-drug antibodies (ADAbs) thresholds for each biologic agent at the different stages of therapy are not currently, accurately defined; a reactive approach is best until higher quality data supporting their role is available.

AGA released a guideline on TDM in IBD this past September. Resources are also available to help your patients better understand TDM.

More on IBD

2018 AGA Postgraduate Course

June 2, 2018

Secure your spot for this clinically focused, multi-topic course that offers immediately applicable information. Held in conjunction with DDW®. Save $75 when you register by April 18.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 14, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 12, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.